Cullen Investment Group LTD. Sells 100 Shares of ICON Public Limited (NASDAQ:ICLR)

Cullen Investment Group LTD. reduced its stake in ICON Public Limited (NASDAQ:ICLR) by 2.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,980 shares of the medical research company’s stock after selling 100 shares during the quarter. Cullen Investment Group LTD.’s holdings in ICON Public were worth $1,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. GAMMA Investing LLC raised its holdings in ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after buying an additional 169 shares during the last quarter. Foyston Gordon & Payne Inc purchased a new position in shares of ICON Public in the third quarter worth approximately $11,672,000. Icon Wealth Advisors LLC grew its position in ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after buying an additional 11,840 shares during the period. First Horizon Advisors Inc. raised its position in ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after acquiring an additional 151 shares during the period. Finally, Arkadios Wealth Advisors boosted its stake in shares of ICON Public by 5.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after acquiring an additional 62 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Trading Down 0.1 %

Shares of NASDAQ:ICLR opened at $217.99 on Tuesday. ICON Public Limited has a 1 year low of $183.38 and a 1 year high of $347.72. The business’s 50 day simple moving average is $211.31 and its 200 day simple moving average is $270.81. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The company has a market capitalization of $17.98 billion, a P/E ratio of 24.30, a P/E/G ratio of 1.54 and a beta of 1.20.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the company earned $3.10 EPS. On average, research analysts anticipate that ICON Public Limited will post 13.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. JPMorgan Chase & Co. dropped their target price on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Royal Bank of Canada started coverage on ICON Public in a research report on Tuesday, January 7th. They set an “outperform” rating and a $263.00 price target on the stock. Baird R W cut ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Barclays dropped their price objective on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Finally, TD Cowen dropped their price target on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, ICON Public presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.